PRESS RELEASE: IVI Illustrates “Insurance Value” Using IVI-RA Model in Latest Research Brief

In a new Value Blueprints research brief, IVI explores the novel concept of “Insurance Value.” New medical technologies not only benefit patients, but also healthy people at risk of future illness. The insurance value arising from the decreased physical risk from illness is a potentially important dimension to consider in value assessment, especially when decisions [...]

2019-07-24T23:44:17-06:00July 25th, 2019|IVI News, Press|

PRESS RELEASE: IVI Releases Public Comments on Non-Small Cell Lung Cancer Value Tool

Thank you for your comments! IVI has released all public feedback received during the open comment period for the IVI-NSCLC model - our open-source platform to assess therapy sequences for EGFR+ non-small cell lung cancer. In the spirit of IVI's mission of collaboration, commitment to transparency, and dedication to iterative improvement, we look forward to [...]

2019-07-18T13:08:44-06:00July 18th, 2019|IVI News, Press|

Heard at ISPOR: Wide Ranging Podcast with IVI on Advanced Value Assessment Methods and the QALY Controversy

The IVI team sat down with the Journal of Clinical Pathways while at ISPOR for an in-depth discussion about why advanced value assessment is needed and how it’s progressing. The team also discussed the QALY – what it is and whether it can be improved. To listen to the podcast or read the transcript, click [...]

2019-06-12T12:48:09-06:00June 12th, 2019|IVI News, Press|

PRESS RELEASE: IVI Launches New Research Brief Series “Value Blueprints”

IVI launches a new research brief series to present research findings and method insights from the OSVP. Let’s sparks a conversation into next-gen value assessment. Read the full press release here.

2019-05-21T13:39:14-06:00May 20th, 2019|IVI News, Press|

PRESS RELEASE: IVI Unveils New Value Assessment Model for Non-Small Cell Lung Cancer

IVI released our initial version of the new Open-Source Value Platform (OSVP) model for non-small cell lung cancer. Specifically, the model provides information on the relative value of sequential treatments for epidermal growth factor receptor positive (EGFR+), non-squamous non-small cell lung cancer (NSCLC). The entirety of the IVI-NSCLC model package, including detailed methods documentation, R [...]

2019-01-31T13:30:16-06:00January 31st, 2019|IVI News, Press|

PRESS RELEASE: IVI’s Patient Research Reveals Importance of Quality of Life in Assessing Non-Small Cell Lung Cancer Therapy Sequence Value

Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]

2018-11-15T16:00:32-06:00November 15th, 2018|IVI News, Press, Research|

PRESS RELEASE: IVI Showcases Recent Research Activities as Part of the Open-Source Value Project at ISPOR EU 2018

Los Angeles, CA – November 13, 2018 – The Innovation and Value Initiative (IVI) – a collaboration dedicated to advancing the science and improving the practice of value assessment in healthcare – will present research at this week’s ISPOR Europe 2018 conference showcasing different elements of the Open-Source Value Project (OSVP) initiative to facilitate assessment [...]

2018-11-14T14:20:56-06:00November 13th, 2018|Events, IVI News, Press|

PRESS RELEASE: IVI Discusses the Open-Source Value Project and Its Relevance in Modernizing Cost-Effectiveness Analysis

ISPOR Conference Examines How New Approaches to Value Assessment May Help Move Toward More Informed Pricing Washington, D.C. –- October 19, 2018 -- At the ISPOR Summit 2018, the lead scientific advisor for the Innovation and Value Initiative (IVI) - a collaboration dedicated to advancing the science and improving the practice of value assessment in [...]

2018-10-22T07:55:22-06:00October 19th, 2018|Events, IVI News, Press|

PRESS RELEASE: IVI’s Executive Director Discusses Moving Beyond the Average in Value Assessment

IVI’s Executive Director Discusses Moving Beyond the Average in Value Assessment at Xtelligent Media’s Value Based Summit 2018 Boston, MA –- October 18, 2018 -- Value Assessment 2.0 requires building assessment models that account for all of the factors that determine value instead of focusing only on cost and clinical benefits, said the executive director [...]

2018-10-18T18:49:30-06:00October 18th, 2018|Events, IVI News, Press|

PRESS RELEASE: IVI Releases Public Feedback and Technical Expert Panel Recommendations for Open-Source Platform Model to Assess Outcomes and Value of Rheumatoid Arthritis Therapies

Priorities Emerged Which Will Shape Version 2.0 of IVI’s RA Model Los Angeles, CA – September 20, 2018 -- The Innovation and Value Initiative (IVI) today released public feedback and recommendations from its Technical Expert Panel (TEP), an objective third party comprised of five leaders in health economics, epidemiology, rheumatology, and patient communities, which the [...]

2018-09-20T09:03:25-06:00September 20th, 2018|IVI News, Press, Research|